Open Access Green as soon as Postprint is submitted to ZB.
Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: Findings from a retrospective, real-world database subanalysis.
Expert Rev. Clin. Immunol. 13, 1199-1206 (2017)
BACKGROUND: We assessed real-world, long-term effectiveness of two marketed sublingual immunotherapy (SLIT) tablets for allergic rhinitis (AR), and their impact on allergic asthma (AA) onset/progression. RESEARCH DESIGN AND METHODS: Retrospective, longitudinal German prescription database subanalysis of AR patients receiving 5- or 1-grass pollen SLIT tablets (n=1,466/1,385), versus patients not using allergy immunotherapy (AIT) (n=71,275). MAIN OUTCOME MEASURES: Primary endpoint: change over time in AR symptomatic medication prescriptions after treatment cessation; secondary endpoints: new asthma onset, and change over time in asthma medication prescriptions during treatment/follow-up periods. RESULTS: Mean number of AR medication prescriptions was significantly decreased during follow-up (of up to 6 years) with both SLIT tablets versus the non-AIT group (p<0.001). Over the full-analysis period, proportions of patients with new-onset asthma were 8.8% (odds ratio: 0.676, p=0.011), 10.3% (odds ratio: 0.720, p=0.060) and 11.6% in the 5- and 1-grass pollen SLIT tablet and non-AIT groups, respectively. For all treatment-analysis periods, both SLIT tablet groups were associated with fewer asthma medication prescriptions versus non-AIT controls. CONCLUSIONS: These findings confirm the real-world benefits of 5- and 1-grass-pollen SLIT tablets in slower AR progression, reduced risk of new asthma onset in the non-asthmatic population, and slower asthma progression in the asthmatic population.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Allergic Rhinitis ; Asthma ; Grass Pollen ; Real-world ; Sublingual Immunotherapy; Controlled-trials; Clinical-trials; Rhinoconjunctivitis; Collaboration; Prevalence; Consensus; Disease; Impact
ISSN (print) / ISBN
1744-666X
Quellenangaben
Volume: 13,
Issue: 12,
Pages: 1199-1206
Publisher
Expert Reviews
Publishing Place
London
Reviewing status
Peer reviewed
Institute(s)
Institute of Epidemiology (EPI)